Waldencast (WALD) Projected to Post Quarterly Earnings on Thursday

Waldencast (NASDAQ:WALD) is expected to announce its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of ($0.11) per share and revenue of $67.80 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 13, 2026 at 3:00 AM ET.

Waldencast (NASDAQ:WALD) last released its earnings results on Monday, November 24th. The company reported ($0.69) EPS for the quarter. The business had revenue of $66.14 million for the quarter. On average, analysts expect Waldencast to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Waldencast Trading Down 1.3%

Shares of Waldencast stock opened at $1.52 on Thursday. Waldencast has a fifty-two week low of $1.45 and a fifty-two week high of $3.51. The business’s fifty day moving average is $1.69 and its two-hundred day moving average is $1.87. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.53 and a quick ratio of 0.67.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Invesco Ltd. purchased a new stake in Waldencast during the second quarter valued at about $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Waldencast by 57.9% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,130 shares of the company’s stock valued at $57,000 after purchasing an additional 8,485 shares in the last quarter. CIBC Asset Management Inc purchased a new stake in shares of Waldencast during the 4th quarter worth about $46,000. Jane Street Group LLC purchased a new stake in shares of Waldencast during the 1st quarter worth about $77,000. Finally, Squarepoint Ops LLC acquired a new stake in Waldencast during the 3rd quarter worth approximately $78,000. Institutional investors and hedge funds own 41.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on WALD shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Waldencast in a research note on Wednesday, January 21st. Jefferies Financial Group started coverage on Waldencast in a research note on Wednesday, January 14th. They issued a “buy” rating and a $2.00 price target on the stock. Telsey Advisory Group downgraded shares of Waldencast from an “outperform” rating to a “market perform” rating and set a $3.00 price objective for the company. in a research note on Tuesday, November 25th. Finally, Canaccord Genuity Group cut their price objective on shares of Waldencast from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, November 25th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Waldencast presently has an average rating of “Moderate Buy” and a consensus target price of $4.42.

About Waldencast

Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians. The company also offers clean makeup products under the Milk Makeup brand. It sells its products to dermatologists, plastic surgeons, and other physicians who focuses on aesthetic and therapeutic skincare, including physicians on site at medical spas, through its direct sales force, as well as through distribution partners.